ProCE Banner Activity

Phase II Study of Acalabrutinib Monotherapy Demonstrates Activity, Safety in Previously Untreated CLL

Slideset Download
Conference Coverage
Early investigation of the next-generation BTK inhibitor acalabrutinib suggests that this agent can be used safely and has promising activity in previously untreated CLL patients, with no disease progression observed at a median follow-up of 10.5 months.

Released: June 08, 2016

Expiration: June 07, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals